Key result
Unilateral adrenal artery embolization is linked to ~17 mmHg lower SBP in idiopathic hyperaldosteronism.
Why the study?
Adrenal artery embolization reduces blood pressure and corrects biochemical abnormalities in idiopathic hyperaldosteronism during short-term follow-up, but long-term efficacy and safety over 24 months remained to be evaluated.
Does unilateral adrenal artery embolization reduce blood pressure and correct biochemical abnormalities in patients with idiopathic hyperaldosteronism?
Cohort (n=109)
Does unilateral adrenal artery embolization reduce blood pressure and correct biochemical abnormalities in patients with idiopathic hyperaldosteronism?
Unilateral adrenal artery embolization provides sustained blood pressure reduction, biochemical correction, and improved cardiac remodeling over 24 months in patients with idiopathic hyperaldosteronism.
Answers are grounded in this paper and cite their sources.
May support embolization in idiopathic hyperaldosteronism; leaves open need for randomized confirmation before practice change.
BACKGROUND: Adrenal artery embolization (AAE) has been shown to reduce blood pressure (BP) and correct biochemical abnormalities in patients with idiopathic hyperaldosteronism (IHA) during short-term 6-12-month follow-ups. This study aimed to evaluate the long-term efficacy and safety of unilateral AAE over a 24-month period. METHODS: The prospective study included 109 IHA patients undergoing unilateral AAE, with 94 completing the 24-month follow-up. Evaluations included office, home and 24-hour ambulatory BP, biochemical markers, renal function, and cardiac function (echocardiography). Medication use and adverse events were documented. RESULTS: At the 24-month follow-up, the office, home, and 24-hour ambulatory systolic BP values decreased by 17.3 ± 23.1, 16.4 ± 21.9, and 9.9 ± 18.6 mmHg, respectively (all P < 0.001), and the diastolic BP values decreased by 8.8 ± 16.1, 7.1 ± 15.8, and 6.4 ± 11.1 mmHg (all P < 0.001). The complete and partial clinical success rates were 14.9% and 50.0%, respectively, whereas those for biochemical success were 13.6% and 45.5%. Abnormal biochemical characteristics, including elevated plasma aldosterone levels, increased aldosterone‒renin ratios (ARRs), plasma renin suppression, and hypokalemia, were significantly improved (all P < 0.01). Improvements in cardiac remodeling and left ventricular (LV) diastolic function were observed, particularly in those with elevated LV mass index (P < 0.05). No evidence of renal impairment or long-term safety concerns was observed. CONCLUSION: Unilateral AAE in IHA patients promotes sustained BP reduction, biochemical correction, improved cardiac remodeling, and enhanced LV diastolic function over 24 months, with no significant long-term safety concerns.
No takes yet. Share an insight, caveat, or question.
Ji et al. (2025) conducted a cohort in Idiopathic hyperaldosteronism (n=109). Unilateral adrenal artery embolization was evaluated on Office systolic blood pressure reduction (mmHg) (p=<0.001). Unilateral adrenal artery embolization in patients with idiopathic hyperaldosteronism reduced office systolic blood pressure by 17.3 mmHg at 24 months.
Synapse has enriched 10 related papers. Consider them for comparative context: